Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C.
Adult
Aged
Aged, 80 and over
Anthropometry
/ methods
Antiviral Agents
/ therapeutic use
Cardiovascular Diseases
/ drug therapy
Comorbidity
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ epidemiology
Female
Heart Disease Risk Factors
Hepacivirus
/ isolation & purification
Hepatitis C
/ complications
Humans
Life Style
Male
Middle Aged
Patient Care Bundles
/ methods
Prevalence
Quality of Life
Sedentary Behavior
Smoking
/ epidemiology
HCV
cardiovascular disease
diabetes mellitus
obesity
quality of life
Journal
BMJ open gastroenterology
ISSN: 2054-4774
Titre abrégé: BMJ Open Gastroenterol
Pays: England
ID NLM: 101660690
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
24
06
2020
revised:
15
07
2020
accepted:
20
07
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
29
6
2021
Statut:
ppublish
Résumé
Hepatitis C virus (HCV) infection is common. Although treatment is effective, with oral antivirals curing >95% of patients, most individuals have comorbidities that persist long term. Therefore, our aim was to determine the prevalence of potentially modifiable health problems in patients with HCV and develop an HCV care bundle to identify and target comorbidities. Cross-sectional, observational single-centre study that recruited consecutive patients with HCV from our viral hepatitis clinics. Data were collected on cardiovascular (CV) risk factors, lifestyle behaviours, anthropometry and health-related quality of life (HRQoL). QRISK 3 was used to predict 10-year CV event risk. 100 patients were recruited (67% male, 93% white, median age 52 years (range 24-80); 71% were treated for HCV; 34% had cirrhosis; 14% had diabetes; 61% had hypertension; 31% had metabolic syndrome; and 54% were smokers). The median 10-year CV event risk was 8.3% (range 0.3%-63%). 45% had a predicted 10-year CV event risk of >10%. Only 10% of individuals were treated with statins and 27% with antihypertensives. 92% had a predicted 'heart age' greater than their chronological age (median difference +7 (-4 to +26) years). HRQoL was reduced in all SF36v2 domains in the cohort. Factors independently associated with HRQoL included cirrhosis, metabolic syndrome, history of mental health disorder, sedentary behaviour and HCV viraemia. A large proportion of patients with HCV presented with increased risk of CV events, and rates of smoking and sedentary behaviour were high, while prescribing of primary prophylaxis was infrequent. HRQoL was also reduced in the cohort. A 'care bundle' was developed to provide a structured approach to treating potentially modifiable health problems.
Identifiants
pubmed: 32847899
pii: bmjgast-2020-000470
doi: 10.1136/bmjgast-2020-000470
pmc: PMC7451276
pii:
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Department of Health
ID : NIHR300760
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: SMcP: consultancy/speakers fees from Abbvie, Allergan, BMS, Cambwick, Gilead, Intercept, MSD, Novartis and Sequana.
Références
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
J Public Health (Oxf). 2019 Dec 20;41(4):700-706
pubmed: 30351415
Gastroenterology. 2016 Jun;150(7):1599-1608
pubmed: 26924097
Heart. 2008 Oct;94(10):1331-2
pubmed: 18701534
Int J Obes (Lond). 2008 Jan;32(1):185-91
pubmed: 17653068
Hepatology. 2015 Aug;62(2):365-74
pubmed: 25847403
PLoS One. 2018 Dec 12;13(12):e0208839
pubmed: 30540839
J Hepatol. 2019 Dec;71(6):1116-1125
pubmed: 31433302
Lancet Gastroenterol Hepatol. 2019 Oct;4(10):794-804
pubmed: 31377134
Frontline Gastroenterol. 2016 Jan;7(1):16-23
pubmed: 26834955
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Hepatology. 2011 Nov;54(5):1547-58
pubmed: 22045672
Rev Endocr Metab Disord. 2018 Dec;19(4):405-420
pubmed: 29322398
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Liver Int. 2019 Jan;39(1):54-59
pubmed: 29893462
Clin Liver Dis. 2017 Aug;21(3):475-486
pubmed: 28689587
Dig Dis Sci. 2020 Jul;65(7):1940-1950
pubmed: 31758432
Harm Reduct J. 2019 Feb 13;16(1):16
pubmed: 30760261
J Hepatol. 2014 Nov;61(1 Suppl):S58-68
pubmed: 25443346
BMC Infect Dis. 2012 Apr 11;12:86
pubmed: 22494445
Clin Microbiol Infect. 2020 Jul;26(7):818-823
pubmed: 31978546
Front Psychol. 2019 Jan 09;9:2666
pubmed: 30687151
Aliment Pharmacol Ther. 2016 Nov;44(10):1030-1038
pubmed: 27666418
Can J Gastroenterol Hepatol. 2018 Oct 3;2018:6095097
pubmed: 30402450
Drug Alcohol Depend. 2015 Aug 1;153:66-71
pubmed: 26096534
Hepatology. 2001 Oct;34(4 Pt 1):809-16
pubmed: 11584380
Gastroenterology. 2019 Mar;156(4):987-996.e8
pubmed: 30445009
Clin Infect Dis. 2020 Mar 3;70(6):1153-1160
pubmed: 30977808
World J Gastroenterol. 2016 Jul 21;22(27):6201-13
pubmed: 27468210
PLoS One. 2019 May 3;14(5):e0215596
pubmed: 31050687
Frontline Gastroenterol. 2013 Apr;4(2):125-129
pubmed: 28839713